Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare.
Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare.
复制标题
使用 SEER-Medicare 对老年多发性骨髓瘤患者进行自体干细胞移植的合并症的费用影响。
DOI：
10.1155/2016/3645623
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Parsons,SusanK
中科院分区：
文献类型：
--
作者：
Shah,GunjanL;Winn,Aaron;Lin,Pei-Jung;Klein,Andreas;Sprague,KellieA;Smith,HedyP;Buchsbaum,Rachel;Cohen,JoshuaT;Miller,KennethB;Comenzo,Raymond;Parsons,SusanK
Comorbidity is more common in older patients and can increase the cost of care by increasing toxicity. Using the SEER‐Medicare database from 2000 to 2007, we examined the costs and life‐year benefit of Auto‐HSCT for MM patients over the age of 65 by evaluating the difference over time relative to comorbidity burden. One hundred ten patients had an Auto‐HSCT in the early time period (2000–2003) and 160 in the late time period (2004–2007). Patients were divided by a Charlson Comorbidity Index (CCI) of 0 or greater than 1 (CCI1+). Median overall survival was 53.5 months for the late time period patients compared to 40.3 months for the early time period patients (p= 0.031). Median costs for CCI0 versus CCI1+ in the early period were, respectively, $70,900 versus $72,000 (100 d); $86,100 versus $98,300 (1 yr); and $139,200 versus $195,300 (3 yrs). Median costs for late period were, respectively, $58,400 versus $60,400 (100 d); $86,300 versus $77,700 (1 yr); and $124,400 versus $110,900 (3 yrs). Comorbidity had a significant impact on survival and cost among early time period patients but not among late time period patients. Therefore, older patients with some comorbidities can be considered for Auto‐HSCT depending on clinical circumstances.
